Filtered By:
Drug: Taxotere
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 2210 results found since Jan 2013.
The oncogenic protein kinase/ATPase RIOK1 is up-regulated via the MYC/E2F transcription factor axis in prostate cancer
In this study, we examined the expression, regulation and therapeutic potential of RIOK1 in PCa. RIOK1 mRNA and protein expression were elevated in PCa tissue samples and correlated with proliferative and protein homeostasis related pathways. RIOK1 was identified as a downstream target gene of the MYC/E2F transcription factors. RIOK1 knock-down and over-expression of the dominant-negative RIOK1-D324A mutant significantly reduced proliferation of PCa cells. Biochemical inhibition of RIOK1 with toyocamycin led to strong anti-proliferative effects in AR-negative and -positive PCa cell lines with EC50 values from 3.5 to 8.8 nM...
Source: Am J Pathol - June 10, 2023 Category: Pathology Authors: Florian Handle Martin Puhr Martina Gruber Chiara Andolfi Georg Sch äfer Helmut Klocker Johannes Haybaeck Peter De Wulf Zoran Culig Source Type: research
A FOXC2 inhibitor, MC-1-F2, as a therapeutic candidate for targeting EMT in castration-resistant prostate cancer
Bioorg Med Chem Lett. 2023 Jun 6:129369. doi: 10.1016/j.bmcl.2023.129369. Online ahead of print.ABSTRACTAndrogen deprivation therapy (ADT) is the major treatment option for advanced prostate cancer. However, prostate cancer can develop into androgen-independent castration-resistant prostate cancer (CRPC) which is resistant to ADT. An alternative treatment strategy for CRPC can be targeting the epithelial-mesenchymal transition (EMT). EMT is governed by a series of transcription factors of which forkhead box protein C2 (FOXC2) is a central mediator. Our previous research into the inhibition of FOXC2 in breast cancer cells l...
Source: Bioorganic and Medicinal Chemistry Letters - June 8, 2023 Category: Chemistry Authors: Maria Castaneda Liandra Rodriguez Jihyun Oh Brittnee Cagle-White Hanna Suh May H Abdel Aziz Jiyong Lee Source Type: research
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
CONCLUSION: Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occurred.PMID:37290035 | DOI:10.1200/JCO.23.00233
Source: Clinical Prostate Cancer - June 8, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Se Hoon Park Jeffrey C Goh Sang Joon Shin Jae Lyun Lee Niven Mehra Ray McDermott N úria Sala-Gonzalez Peter C Fong Richard Greil Margitta Retz Juan Pablo Sade Patricio Yanez Yi-Hsiu Huang Stephen D Begbie Rustem Airatovich Gafanov Source Type: research
Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel
CONCLUSION: The conditional OS for patients undergoing docetaxel chemotherapy tends to plateau over time, with the main drop in conditional OS happening during the first year from initiating docetaxel treatment. That is the longer a patient survives, the more likely they are to survive further. This prognostic information could be a useful tool for a more accurate tailoring of both follow-up and therapies.PATIENT SUMMARY: In this report, we looked at the future survival in months of patients with metastatic castration resistant prostate cancer on chemotherapy who have already survived a certain period. We found that the lo...
Source: Cancer Control - June 8, 2023 Category: Cancer & Oncology Authors: Daniele Modonutti Sami E Majdalany Mohit Butaney Matthew J Davis Nicholas Corsi Akshay Sood Quoc-Dien Trinh Alexander P Cole Craig G Rogers Giacomo Novara Firas Abdollah Source Type: research
High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment
This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast cancer patients receiving docetaxel (75 mg/m2)-containing regimens were divided into 4 and 8 mg/day DEX groups, with each DEX dose administered on days 2-4 and retrospectively assessed. Incidence of greater than or equal to grade 2 DIFR was significantly lower in the 8 mg group (13.0%) compared to the 4 mg group (39.6%, P = 0.001). All-grade DIFR was also less in the 8 mg group (P = 0.01). Furthermore, the maximum variation of body weight was significantly lower in the 8 mg group (P = 0.0003). These...
Source: Cancer Control - June 7, 2023 Category: Cancer & Oncology Authors: Yoshitaka Saito Ryota Kanno Yoh Takekuma Takashi Takeshita Tomohiro Oshino Mitsuru Sugawara Source Type: research
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
CONCLUSIONS: Our findings support CXCR4 as a novel therapeutic target and a predictive biomarker for trastuzumab resistance in HER2+ breast cancer.PMID:37280713 | DOI:10.1186/s13058-023-01665-w
Source: Cell Research - June 6, 2023 Category: Cytology Authors: Shuying Liu Shelly M Xie Wenbin Liu Mihai Gagea Ariella B Hanker Nguyen Nguyen Akshara Singareeka Raghavendra Gloria Yang-Kolodji Fuliang Chu Sattva S Neelapu Adriano Marchese Samir Hanash Johann Zimmermann Carlos L Arteaga Debasish Tripathy Source Type: research
Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening
Sci Rep. 2023 Jun 3;13(1):9043. doi: 10.1038/s41598-023-35950-7.ABSTRACTEnzalutamide, docetaxel, and cabazitaxel treatment resistance is a major problem in metastatic castration resistant prostate cancer (mCRPC), but the underlying genetic determinants are poorly understood. To identify genes that modulate treatment response to these drugs, we performed three genome-wide CRISPR/Cas9 knockout screens in the mCRPC cell line C4. The screens identified seven candidates for enzalutamide (BCL2L13, CEP135, E2F4, IP6K2, KDM6A, SMS, and XPO4), four candidates for docetaxel (DRG1, LMO7, NCOA2, and ZNF268), and nine candidates for ca...
Source: Clinical Prostate Cancer - June 3, 2023 Category: Cancer & Oncology Authors: Jakob Haldrup Simone Weiss Linn éa Schmidt Karina Dalsgaard S ørensen Source Type: research
